Recce Pharmaceuticals, who are currently developing a new class of synthetic antibiotics, has appointed Dr John Prendergast to its board as an independent non-executive director.
Dr Prendergast brings significant international experience in commercialising pharmaceuticals for global markets, most notably in the US.
He is currently chairman and co-founder of Palatin Technologies, a US biotechnology company capitalised at more than $260m, developing therapeutics for diseases with significant unmet medical need; lead director of Heat Biologics and co-founder/executive chairman of Nejo.
Dr Prendergast said: "I am pleased to join Recce's Board at a pivotal time in the company’s development, as its new class of antibiotics continues to show significant promise in tackling the global health problem of superbugs. I look forward to supporting the company's development program."
Executive chairman Dr Graham Melrose said: “We welcome Dr Prendergast to the board at a key point in our regulatory and commercial development. His experience in the US market will be invaluable as we progress our lead compound towards clinical trials in the US.”
